关键的见解为密集治疗师在吉兰-巴雷综合征的关键见解
Nicolas Weiss1,2,3, Clémence Marois4,5, Loic Le Guennec4,6
1Département de neurologie, Service de Médecine Intensive Réanimation à orientation neurologique, Sorbonne Université, AP-HP.Sorbonne Université, Hôpital de la Pitié-Salpêtrière, 47-83, boulevard de l'hôpital, Paris, 75013, France. nicolas.weiss@aphp.fr.
Annals of intensive care
|May 20, 2025
概括
吉兰-巴雷综合征 (GBS) 是一种免疫介导的多神经病变,导致急性松四肢. 诊断包括临床病史,腰部穿刺和脑电图,IVIg或PLEX等治疗提供了有利的预后.
科学领域:
- 神经学 神经学
- 免疫学 免疫学 免疫学
- 临床医学 临床医学
背景情况:
- 吉兰-巴雷综合征 (GBS) 是全球急性松四肢的一个重要原因.
- 这是一种免疫介导的多神经病变,通常是由感染或接种疫苗引发的.
- 每年每10万人中GBS发病率为1-2例.
研究的目的:
- 总结目前对吉兰-巴雷综合征 (GBS) 病理生理学,诊断和管理的理解.
- 根据电生理学发现,强调将GBS分为亚型的分类.
- 讨论当前和未来的治疗策略和预后指标.
主要方法:
- 诊断依赖于临床病史,腰部穿刺 (LP) 和电神经图 (ENMG).
- 分类包括急性炎症性脱髓性多神经病变 (AIDP),急性运动轴突神经病变 (AMAN) 和急性运动感官轴突神经病变 (AMSAN).
- 治疗包括静脉注射免疫球蛋白 (IVIg) 或治疗性血交换 (PLEX),以及支持性护理.
主要成果:
- GBS病理生理学涉及到分子模仿,准神经结构,如质酶和髓.
- 像IVIg和PLEX这样的治疗策略与一般有利的结果有关.
- 死亡率很低 (<5%),但神经系统的后果可能会持续存在.
结论:
- 治理GBS需要及时诊断和亚型分化才能有效治疗.
- 新型疗法,包括补充向治疗,正在研究中.
- 像神经纤维光链这样的生物标志物可能会改善预后预测和患者管理.
相关概念视频
01:15Myasthenia Gravis: Diagnostic Tests
593
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
593
01:20Myasthenia Gravis: Overview and Treatment
1.1K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.1K
01:19Depolarizing Blockers: Pharmocokinetics
299
Depolarizing blockers are administered through intravenous injection. Succinylcholine is the most common choice of depolarizing blockers in emergency clinical practices. Although they have a rapid onset, they readily diffuse away from the motor end plate into the extracellular fluid. They are metabolized by enzymes such as liver butyrylcholinesterase and plasma pseudocholinesterases. This produces a short duration of action, typically 5-10 minutes long, unlike nondepolarizing blockers, which...
299
01:28Depolarizing Blockers: Mechanism of Action
1.1K
Depolarizing blockers act on skeletal muscle fibers' membranes and induce their depolarization. Most depolarizing blockers have two quaternary N+ atoms that bind the nicotinic acetylcholine receptors and cause neuromuscular blockade within minutes.
Succinylcholine is the most commonly used depolarizing blocker. Chemically, it constitutes two molecules of acetylcholine joined together by an acetate methyl group. They act on the receptors in the same way as acetylcholine. Because...
Succinylcholine is the most commonly used depolarizing blocker. Chemically, it constitutes two molecules of acetylcholine joined together by an acetate methyl group. They act on the receptors in the same way as acetylcholine. Because...
1.1K